Research-The Hong Kong University

Research Achievements More

During the COVID-19 pandemic, HKU-SZH has made numerous achievements in the rese...

Achievements

Academic News More

As of October 2021, the Hospital had led over 227 scientific and technological planning programs with R&D funds of over RMB 110 million. These included 35 programs of the National Natural Science Foundation of China (NSFC), two special programs for international cooperation of the NSFC, and two sub-projects of a national key research program. The research quality and output have been improving steadily with 1,324 papers published by either the lead author or corresponding author from the Hospital. Among these, 576 were included in the Science Citation Index Expanded (SCIE), 60 had Impact Factor (IF) >10, and 348 were published in core journals. 46 invention patent applications were filed and nine were granted, with three filed under the Patent Cooperation Treaty (PCT). 68 utility model patents were applied for and 47 were granted. The patent "Mobile Blood Bank and Closed-Loop Data Management System" won the second prize of the Innovation and Invention Award of the Chinese Nursing Association. Three patents were successfully transferred. During the COVID-19 pandemic, HKU-SZH has made numerous achievements in the research of the novel coronavirus, including its origin, transmission, early detection, early diagnosis, risk stratification, treatment strategies, drug R&D, and infection control inside and outside the Hospital. 37 papers were published in Lancet, NEJM, Nature, Cell, and other journals by either the lead author or corresponding author from the Hospital, with the total impact factor exceeding 360. In view of the outstanding contribution to COVID-19 prevention and control, HKU-SZH was awarded the first prize of the Shenzhen Science and Technology Progress Award in the social welfare category for its "Application of Clinical Microbiology and Imaging in the Prevention and Treatment of COVID-19 infections" in 2021.

Sanming Project

Research Platform

Clinical Trials Center

Join Us Information Bulletin Download More More More

Postdoctoral Programs

Medical Ethics Committee

Introduction

The Medical Ethics Committee of The University of Hong Kong - Shenzhen Hospital (HKU - SZH) was formally established in March 2013. Its purpose is to supervise all diagnosis, treatment and research carried out within the hospital, and its mission is to protect the rights and interests, safety, and health of patients and research participants from an ethical perspective. To standardize the management and operation of the Ethics Committee, the hospital drew on the management model of the Research Ethics Committee of the Hong Kong West Cluster under the Hospital Authority of Hong Kong, and formally issued the Standard Operating Procedures (SOP) for the Medical Ethics Committee of HKU-SZH on September 22, 2014, which has now been updated to the 6th edition. This SOP formulates detailed operational guidelines for the organizational management and operation of the Medical Ethics Committee. The Medical Ethics Committee of HKU - SZH is a first-tier committee of the hospital. It holds two plenary meetings every year to listen to the reports of each second-tier committee and discuss ethics-related issues. Based on functional responsibilities, the Medical Ethics Committee has established several second-tier ethics committees under it, including Research Ethics Committee, Clinical Trial Ethics Committee, Clinical Technology Ethics Committee, Prenatal Diagnosis Ethics Committee, Human Organ Transplant Ethics Committee, and Stem Cell Clinical Research Ethics Committee. Chairmen and vice chairmen are appointed to each second-tier committee, which is responsible for reviewing ethics-related projects in their respective professional fields. In July 2025, the hospital adjusted the organizational structure of its ethics committee system, and Reproductive Medicine Ethics Committee was designated as an independent first-tier committee.